These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 31037141

  • 21. Crocin inhibits RANKL-induced osteoclast formation and bone resorption by suppressing NF-κB signaling pathway activation.
    Fu L, Pan F, Jiao Y.
    Immunobiology; 2017 Apr; 222(4):597-603. PubMed ID: 27871781
    [Abstract] [Full Text] [Related]

  • 22. Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
    Jia Y, Jiang J, Lu X, Zhang T, Zhao K, Han W, Yang W, Qian Y.
    J Cell Physiol; 2019 May; 234(5):7498-7509. PubMed ID: 30471112
    [Abstract] [Full Text] [Related]

  • 23. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X, Li Z, Yang Z, Zheng C, Jing J, Chen Y, Ye X, Lian X, Qiu W, Yang F, Tang J, Xiao J, Liu M, Luo J.
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [Abstract] [Full Text] [Related]

  • 24. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Li L, Sapkota M, Kim SW, Soh Y.
    Eur J Pharmacol; 2016 Apr 15; 777():17-25. PubMed ID: 26923730
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G, Wang FF, Li T, Jia DD, Shen Y, Xu HC.
    Med Sci Monit; 2018 Apr 26; 24():2569-2577. PubMed ID: 29698379
    [Abstract] [Full Text] [Related]

  • 27. Aminothiazoles inhibit osteoclastogenesis and PGE2 production in LPS-stimulated co-cultures of periodontal ligament and RAW 264.7 cells, and RANKL-mediated osteoclastogenesis and bone resorption in PBMCs.
    Kats A, Gerasimcik N, Näreoja T, Nederberg J, Grenlöv S, Lagnöhed E, Desai S, Andersson G, Yucel-Lindberg T.
    J Cell Mol Med; 2019 Feb 26; 23(2):1152-1163. PubMed ID: 30506812
    [Abstract] [Full Text] [Related]

  • 28. PF-3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses Osteoclastogenesis through ERK and NF-κB Pathways In Vitro and Alveolar Bone Loss In Vivo.
    Ihn HJ, Kim YS, Lim S, Bae JS, Jung JC, Kim YH, Park JW, Wang Z, Koh JT, Bae YC, Baek MC, Park EK.
    Int J Mol Sci; 2021 Feb 15; 22(4):. PubMed ID: 33671948
    [Abstract] [Full Text] [Related]

  • 29. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY, Lee KS, Yi SH, Kook SH, Lee JC.
    PLoS One; 2013 Feb 15; 8(12):e80873. PubMed ID: 24324641
    [Abstract] [Full Text] [Related]

  • 30. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
    Joung YH, Darvin P, Kang DY, Sp N, Byun HJ, Lee CH, Lee HK, Yang YM.
    PLoS One; 2016 Feb 15; 11(7):e0159891. PubMed ID: 27447722
    [Abstract] [Full Text] [Related]

  • 31. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
    Sun X, Zhang J, Wang Z, Liu B, Zhu S, Zhu L, Peng B.
    Theranostics; 2019 Feb 15; 9(18):5183-5199. PubMed ID: 31410209
    [Abstract] [Full Text] [Related]

  • 32. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
    Naidu VG, Dinesh Babu KR, Thwin MM, Satish RL, Kumar PV, Gopalakrishnakone P.
    Chem Biol Interact; 2013 Apr 25; 203(2):467-79. PubMed ID: 23333834
    [Abstract] [Full Text] [Related]

  • 33. Anti-osteoclastogenic activity of isoliquiritigenin via inhibition of NF-κB-dependent autophagic pathway.
    Liu S, Zhu L, Zhang J, Yu J, Cheng X, Peng B.
    Biochem Pharmacol; 2016 Apr 15; 106():82-93. PubMed ID: 26947453
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of Lipopolysaccharide-Induced Inflammatory Bone Loss by Saikosaponin D is Associated with Regulation of the RANKL/RANK Pathway.
    Wu X, Zhao K, Fang X, Lu F, Zhang W, Song X, Chen L, Sun J, Chen H.
    Drug Des Devel Ther; 2021 Apr 15; 15():4741-4757. PubMed ID: 34848946
    [Abstract] [Full Text] [Related]

  • 35. Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling.
    Thummuri D, Jeengar MK, Shrivastava S, Nemani H, Ramavat RN, Chaudhari P, Naidu VG.
    Pharmacol Res; 2015 Sep 15; 99():63-73. PubMed ID: 26022736
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-κB and MAPKs signaling pathways.
    Liang S, Nian Z, Shi K.
    Biochem Biophys Res Commun; 2020 Jun 11; 526(4):1028-1035. PubMed ID: 32321638
    [Abstract] [Full Text] [Related]

  • 37. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC, Lee C, Kim JY, Oh HM, So HS, Lee MS, Rho MC, Oh J.
    Biol Pharm Bull; 2013 Jun 11; 36(11):1779-86. PubMed ID: 23985829
    [Abstract] [Full Text] [Related]

  • 38. NF-κB pathway inhibition by anthrocyclic glycoside aloin is key event in preventing osteoclastogenesis in RAW264.7 cells.
    Pengjam Y, Madhyastha H, Madhyastha R, Yamaguchi Y, Nakajima Y, Maruyama M.
    Phytomedicine; 2016 Apr 15; 23(4):417-28. PubMed ID: 27002412
    [Abstract] [Full Text] [Related]

  • 39. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
    Mol Pharmacol; 2010 Jan 15; 77(1):17-25. PubMed ID: 19828731
    [Abstract] [Full Text] [Related]

  • 40. Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways.
    Liu T, Jiang L, Xiang Z, Li J, Zhang Y, Xiang T, Wang W, Li X, Jia Y, Huang X, Lu X, Xu H, Wang X, Sheng J.
    Biomed Pharmacother; 2022 Jul 15; 151():113140. PubMed ID: 35605290
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.